Announcements Trials
Browse Landscape

Status

Terminated 2Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Lung Neoplasms 4Stomach Neoplasms 3Uterine Cervical Neoplasms 1Smoking 1Recurrence 1Pulmonary Disease, Chronic Obstructive 1Platelet Glycoprotein IV Deficiency 1Pediatric Brain Tumor 1Pancreatic Cyst 1Ovarian Neoplasms 1Osteosarcoma 1Neuroendocrine Tumors 1Neoplasms 1Melanoma 1Lymphoma 1Locally Advanced Pancreatic Cancer 1Gastrointestinal Neoplasms 1Fatty Liver 1Cysts 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Anus Neoplasms 1Adenocarcinoma 1

Interventions

pembrolizumab 54Nivolumab 50Ipilimumab 28Cyclophosphamide 16binimetinib 10Specimen Handling 10Magnetic Resonance Spectroscopy 10fludarabine 9Radiosurgery 9relatlimab 8encorafenib 8Opdualag 8Biopsy 8aldesleukin 7Interleukin-2 7atezolizumab 6Immunotherapy 6Blood Specimen Collection 6cemiplimab 5CTLA-4 Antigen 5Bevacizumab 5trametinib 4fludarabine phosphate 4dabrafenib 4Temozolomide 4Paclitaxel 4Immune Checkpoint Inhibitors 4spartalizumab 3Surgical Procedures, Operative 3Metformin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Melanoma × Tomography, X-Ray Computed × Clear all
NCT06199713 2026-01-20

Correlating Early FDG PET/CT and ctDNA in Immune Checkpoint Inhibitor (ICI)-Treated Melanoma Patients

University of Wisconsin, Madison

Recruiting
24 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡